GT Biopharma (GTBP) Institutional Ownership $2.94 -0.07 (-2.33%) (As of 10/31/2024 ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for GT Biopharma (NASDAQ:GTBP)CurrentInstitutional OwnershipPercentage8.15%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$4.84MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$326.26K Get GTBP Insider Trade Alerts Want to know when executives and insiders are buying or selling GT Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data GTBP Institutional Buying and Selling by Quarter Ad Weiss RatingsProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. GT Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/8/2024 DekaBank Deutsche Girozentrale978,358$2.77M0.0%-10.5%69.044% 6/4/2024 DekaBank Deutsche Girozentrale1,093,645$47.45M0.1%N/A77.017% 8/2/2023Bank of Montreal Can596,240$262K0.0%N/A1.596% 1/23/2023 Baskin Financial Services Inc.151,354$134K0.0%N/A0.466% 11/7/2022Virtu Financial LLC24,864$44K0.0%N/A0.076% 5/5/2022Russell Investments Group Ltd.11,007$31K0.0%N/A0.033% Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 5/2/2022 Allspring Global Investments Holdings LLC25,782$74K0.0%N/A0.078% 4/20/2022Sigma Planning Corp21,400$62K0.0%N/A0.067% 2/14/2022Gordian Capital Singapore Pte Ltd35,000$107K0.1%N/A0.114% 2/9/2022 Compagnie Lombard Odier SCmA30,000$92K0.0%+100.0%0.098% 2/4/2022Crumly & Associates Inc.32,163$85K0.0%N/A0.105% 2/3/2022 Brighton Jones LLC11,288$34K0.0%N/A0.037% 1/31/2022Commonwealth Equity Services LLC11,052$33K0.0%N/A0.036% 11/16/2021Two Sigma Advisers LP51,100$344K0.0%+243.0%0.242% 11/16/2021Two Sigma Investments LP162,823$1.10M0.0%N/A0.771% 11/15/2021Marshall Wace LLP16,577$112K0.0%-35.7%0.078% 11/15/2021Franklin Resources Inc.28,500$192K0.0%N/A0.135% 11/12/2021Renaissance Technologies LLC84,700$571K0.0%N/A0.401% 11/12/2021Geode Capital Management LLC424,279$2.86M0.0%+22.4%2.008% 11/10/2021Goldman Sachs Group Inc.52,426$353K0.0%N/A0.248% 11/9/2021BlackRock Inc.1,155,228$7.79M0.0%-18.3%5.468% 11/8/2021State Board of Administration of Florida Retirement System18,224$123K0.0%N/A0.086% 11/8/2021Russell Investments Group Ltd.9,642$64K0.0%N/A0.046% 11/5/2021 Welch Group LLC10,000$67K0.0%N/A0.047% 11/4/2021Deutsche Bank AG11,400$77K0.0%-25.7%0.054% 11/2/2021 New York State Common Retirement Fund8,230$55K0.0%-59.7%0.039% 8/25/2021Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/17/2021Metropolitan Life Insurance Co NY8,782$136K0.0%N/A0.042% 8/17/2021MetLife Investment Management LLC11,471$178K0.0%N/A0.054% 8/17/2021Citadel Advisors LLC510,058$7.91M0.0%N/A2.414% 8/16/2021California State Teachers Retirement System32,878$510K0.0%N/A0.156% 8/16/2021Charles Schwab Investment Management Inc.57,993$899K0.0%N/A0.274% 8/16/2021State Street Corp374,704$5.81M0.0%N/A1.773% 8/16/2021Nuveen Asset Management LLC82,151$1.27M0.0%N/A0.389% 8/16/2021Marshall Wace LLP25,792$400K0.0%N/A0.122% 8/13/2021Northern Trust Corp225,457$3.50M0.0%+555.6%1.067% 8/13/2021Geode Capital Management LLC346,606$5.37M0.0%+165.8%1.641% 8/13/2021Vanguard Group Inc.982,269$15.23M0.0%+267.0%4.649% 8/12/2021Legal & General Group Plc2,524$39K0.0%N/A0.012% 8/12/2021JPMorgan Chase & Co.9,155$142K0.0%N/A0.043% The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows,8/12/2021The Manufacturers Life Insurance Company13,758$213K0.0%N/A0.065% 8/11/2021Bank of New York Mellon Corp58,711$910K0.0%N/A0.278% 8/11/2021BlackRock Inc.1,413,391$21.91M0.0%N/A6.690% 8/11/2021Deutsche Bank AG15,349$237K0.0%N/A0.073% 8/10/2021Citigroup Inc.6,134$95K0.0%N/A0.029% 8/6/2021Ameritas Investment Partners Inc.1,870$29K0.0%N/A0.009% 8/5/2021Rhumbline Advisers18,634$289K0.0%N/A0.088% 8/2/2021 New York State Common Retirement Fund20,400$316K0.0%N/A0.097% 8/2/2021Advisor Group Holdings Inc.2,943$45K0.0%+108.3%0.014% 7/31/2021 Davy Global Fund Management Ltd35,113$544K0.1%+33.4%0.166% 7/15/2021 Compagnie Lombard Odier SCmA15,000$233K0.0%N/A0.071% 7/6/2021Silverleafe Capital Partners LLC104,000$1.61M0.6%N/A0.492% 5/19/2021Virtu Financial LLC22,741$156K0.0%N/A0.080% 5/19/2021Squarepoint Ops LLC16,543$113K0.0%N/A0.058% 5/18/2021Millennium Management LLC27,895$191K0.0%N/A0.098% 5/17/2021Royal Bank of Canada24,542$167K0.0%N/A0.086% 5/12/2021Northern Trust Corp34,387$235K0.0%N/A0.121% 5/12/2021Geode Capital Management LLC130,388$891K0.0%N/A0.459% 5/12/2021UBS Group AG3,918$27K0.0%N/A0.014% 5/11/2021 Davy Global Fund Management Ltd26,321$180K0.0%N/A0.093% (Data available from 1/1/2016 forward) GTBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of GTBP shares? During the previous two years, the following institutional investors and hedge funds held shares of GT Biopharma shares: DekaBank Deutsche Girozentrale ($2.77M), Bank of Montreal Can ($262K), and Baskin Financial Services Inc. ($134K), Virtu Financial LLC ($44K).Learn more on GTBP's institutional investors. What percentage of GT Biopharma stock is owned by institutional investors? 8.15% of GT Biopharma stock is owned by institutional investors. Learn more on GTBP's institutional investor holdings. Which institutional investors have been buying GT Biopharma stock? The following institutional investors have purchased GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($1.09M), Bank of Montreal Can ($596.24K), Baskin Financial Services Inc. ($151.35K), and Virtu Financial LLC ($24.86K). How much institutional buying is happening at GT Biopharma? Institutional investors have bought a total of 1,866,103 shares in the last 24 months. This purchase volume represents approximately $15.76M in transactions. Which GT Biopharma major shareholders have been selling company stock? The following institutional investors have sold GT Biopharma stock in the last 24 months: DekaBank Deutsche Girozentrale ($115.29K). How much institutional selling is happening at GT Biopharma? Institutional investors have sold a total of 115,287 shares in the last 24 months. This volume of shares sold represents approximately $326.26K in transactions. Related Companies Jaguar Health Major Shareholders Talphera Major Shareholders Synlogic Major Shareholders MIRA Pharmaceuticals Major Shareholders Unicycive Therapeutics Major Shareholders Kazia Therapeutics Major Shareholders PharmaCyte Biotech Major Shareholders Cara Therapeutics Major Shareholders Indaptus Therapeutics Major Shareholders IN8bio Major Shareholders This page (NASDAQ:GTBP) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.